Korro Bio, Inc. (KRRO) stock
KRRONasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.61−0.70 (-4.89%)
Close on Nov 13, 2026Market cap $200.42MP/E –Yield –
Korro Bio cash
Cash and short-term investments held at the end of each period.
Korro Bio's cash was $104.99M at Sep 30, 2026. For fiscal 2025 it was $75.16M, down 40.4% from the year before. The highest annual figure on record is $220.34M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $75.16M | -40.4% |
| FY2024 | Dec 31, 2024 | $126.10M | -24.1% |
| FY2023 | Dec 31, 2023 | $166.15M | +200.7% |
| FY2022 | Dec 31, 2022 | $55.25M | -57.7% |
| FY2021 | Dec 31, 2021 | $130.71M | -40.7% |
| FY2020 | Dec 31, 2020 | $220.34M | +1.4% |
| FY2019 | Dec 31, 2019 | $217.36M | +415.2% |
| FY2018 | Dec 31, 2018 | $42.19M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $104.99M | +13.5% |
| Q2 FY2026 | Jun 30, 2026 | $115.04M | +19.4% |
| Q1 FY2026 | Mar 31, 2026 | $113.97M | -0.9% |
| Q4 FY2025 | Dec 31, 2025 | $75.16M | -40.4% |
| Q3 FY2025 | Sep 30, 2025 | $92.48M | -32.5% |
| Q2 FY2025 | Jun 30, 2025 | $96.36M | -38.8% |
| Q1 FY2025 | Mar 31, 2025 | $114.95M | -17.2% |
| Q4 FY2024 | Dec 31, 2024 | $126.10M | -24.1% |
| Q3 FY2024 | Sep 30, 2024 | $137.00M | +228.3% |
| Q2 FY2024 | Jun 30, 2024 | $157.43M | +238.7% |
| Q1 FY2024 | Mar 31, 2024 | $138.80M | +108.3% |
| Q4 FY2023 | Dec 31, 2023 | $166.15M | +200.7% |
| Q3 FY2023 | Sep 30, 2023 | $41.72M | -58.0% |
| Q2 FY2023 | Jun 30, 2023 | $46.48M | -58.1% |
| Q1 FY2023 | Mar 31, 2023 | $66.65M | -43.2% |
| Q4 FY2022 | Dec 31, 2022 | $55.25M | -57.7% |
| Q3 FY2022 | Sep 30, 2022 | $99.35M | -32.9% |
| Q2 FY2022 | Jun 30, 2022 | $111.02M | -34.3% |
| Q1 FY2022 | Mar 31, 2022 | $117.36M | -39.8% |
| Q4 FY2021 | Dec 31, 2021 | $130.71M | -40.7% |
| Q3 FY2021 | Sep 30, 2021 | $148.07M | -34.0% |
| Q2 FY2021 | Jun 30, 2021 | $168.89M | -13.6% |
| Q1 FY2021 | Mar 31, 2021 | $194.91M | -5.4% |
| Q4 FY2020 | Dec 31, 2020 | $220.34M | +1.4% |
| Q3 FY2020 | Sep 30, 2020 | $224.23M | +35.6% |
| Q2 FY2020 | Jun 30, 2020 | $195.38M | +363.1% |
| Q1 FY2020 | Mar 31, 2020 | $206.11M | – |
| Q4 FY2019 | Dec 31, 2019 | $217.36M | – |
| Q3 FY2019 | Sep 30, 2019 | $165.32M | – |
| Q4 FY2018 | Dec 31, 2018 | $42.19M | – |
See a number that looks wrong?